The company said during a conference call following release of its Q1 2025 results that it purchases roughly 80 percent of its supplies from sources within the US.

The Swiss healthcare firm said that the money will be used to expand its R&D, manufacturing, and distribution operations in the US.

The Australian precision diagnostics firm said it will use the money to support the launch of its proteomic tests in Australia and the US.

The company's investment in diagnostics firm Recipe is part of an effort to develop its DART mass spec tech for therapeutic drug monitoring and drugs of abuse testing.

The company has completed its FDA submission for the system and inked a deal with UAE-based healthcare provider Burjeel Holdings to deploy the system in its facilities.

Labcorp also becomes a referral lab for the system's seven hospitals and clinical labs and will open three new patient service centers.

Last week, readers were most interested in a story about how the FDA could exert authority over LDTs in the future.

The company, also known as DRW, shared early data on its forthcoming multiplex qPCR-based platform and infectious disease ...

Tempus AI has announced the formation of its advisory board of medical professionals: ...

The blood test detects a protein biomarker to aid in the diagnosis of axial spondyloarthritis, which is often mistaken for lower back pain.

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.